|
|
Post by jonny80s on Aug 21, 2020 8:02:28 GMT -5
Read somewhere recently that rlftf formerly mindobiotech sold uthr the rights to Aviptadil production some time ago. So there is a loose connection between mnkd and rlftf.....
Anyone care to speculate?
|
|
|
|
Post by goyocafe on Aug 21, 2020 8:12:47 GMT -5
Read somewhere recently that rlftf formerly mindobiotech sold uthr the rights to Aviptadil production some time ago. So there is a loose connection between mnkd and rlftf..... Anyone care to speculate? Did UTHR buy all indications or just ED? The new development for COVID appears to have a life of its own with no mention of UTHR. Do you have a link? |
|
|
|
Post by mango on Aug 21, 2020 8:16:18 GMT -5
Read somewhere recently that rlftf formerly mindobiotech sold uthr the rights to Aviptadil production some time ago. So there is a loose connection between mnkd and rlftf..... Anyone care to speculate? It would be helpful if you would provide some links about it to help facilitate discussion. |
|
|
|
Post by jonny80s on Aug 21, 2020 8:20:45 GMT -5
Seems that the indication was PAH, and that UTHR would be responsible for development and commercialization of the Aviptadil platform.
This was sometime ago, who knows what has happened since then. I don’t have a link it was a screen shot of pipelinereview.com; I have no more info than that.
My crazy idea is that if they already have a connection with United and are working on an inhaled version maybe just maybe... mnkd will be involved. Grasping at straws, most likely.
|
|
|
|
Post by uvula on Aug 21, 2020 8:38:44 GMT -5
Rlftf. $.60/share. Down %15 today. Sounds like the type of company mnkd would work with.
|
|
|
|
Post by Clement on Aug 21, 2020 8:46:08 GMT -5
10 years ago "February 03, 2010 01:34 PM Eastern Standard Time SILVER SPRING, Md. & STANS, Switzerland--(BUSINESS WIRE)--After completion by mondoBIOTECH (SIX: RARE) of a Phase II study where inhaled Aviptadil was shown to have a unique safety profile and promising signals of long term efficacy over currently approved therapies in patients affected by Pulmonary Arterial Hypertension (PAH), United Therapeutics Corporation’s Lung Rx subsidiary and mondoBIOTECH finalized a global strategic partnership focused on the development of Aviptadil for a range of indications, as for example PAH, Sarcoidosis, Idiopathic Pulmonary Fibrosis (IPF) and Acute Respiratory Distress Syndrome (ARDS). The platform can generate more than 1 billion CHF turnover." www.businesswire.com/news/home/20100203006603/en/Lung-Rx-LLC-Subsidiary-United-Therapeutics-Corporation |
|
|
|
Post by jonny80s on Aug 21, 2020 8:52:23 GMT -5
Thank you clement for finding the dates on that. Like I said earlier a relationship is already there... Who knows?
|
|
|
|
Post by itellthefuture777 on Aug 21, 2020 9:06:41 GMT -5
Read somewhere recently that rlftf formerly mindobiotech sold uthr the rights to Aviptadil production some time ago. So there is a loose connection between mnkd and rlftf..... Anyone care to speculate? rltf's brothers-in-law's neighbor's kids friends taxicab driver's pal? |
|
